| Literature DB >> 33397956 |
Carleen Klumpp-Thomas1,2, Heather Kalish3, Matthew Drew4, Sally Hunsberger5, Kelly Snead4, Michael P Fay5, Jennifer Mehalko4, Anandakumar Shunmugavel2, Vanessa Wall4, Peter Frank4, John-Paul Denson4, Min Hong4, Gulcin Gulten4, Simon Messing4, Jennifer Hicks3, Sam Michael1, William Gillette4, Matthew D Hall1, Matthew J Memoli6, Dominic Esposito4, Kaitlyn Sadtler7.
Abstract
The extent of SARS-CoV-2 infection throughout the United States population is currently unknown. High quality serology is key to avoiding medically costly diagnostic errors, as well as to assuring properly informed public health decisions. Here, we present an optimized ELISA-based serology protocol, from antigen production to data analyses, that helps define thresholds for IgG and IgM seropositivity with high specificities. Validation of this protocol is performed using traditionally collected serum as well as dried blood on mail-in blood sampling kits. Archival (pre-2019) samples are used as negative controls, and convalescent, PCR-diagnosed COVID-19 patient samples serve as positive controls. Using this protocol, minimal cross-reactivity is observed for the spike proteins of MERS, SARS1, OC43 and HKU1 viruses, and no cross reactivity is observed with anti-influenza A H1N1 HAI. Our protocol may thus help provide standardized, population-based data on the extent of SARS-CoV-2 seropositivity, immunity and infection.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33397956 PMCID： PMC7782755 DOI： 10.1038/s41467-020-20383-x
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919